Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing novel therapies for life-threatening immune and thrombotic conditions. Its portfolio targets gaps in acute and chronic anticoagulant treatment, with programs designed for patients whose needs may not be adequately addressed by existing options.

The lead program, CAD-1005, is an investigational 12-LOX inhibitor being developed for heparin-induced thrombocytopenia (HIT), a serious immune-mediated condition associated with blood clots. Unlike therapies focused on preventing clotting complications, CAD-1005 is designed to target a pathway involved in the underlying immune response. It has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and orphan drug status from the European Medicines Agency. The company is also developing second-generation oral 12-LOX therapies.

Tecarfarin is a late-stage oral vitamin K antagonist under development for chronic anticoagulation in people with end-stage kidney disease and atrial fibrillation, and patients with implanted left ventricular assist devices. Frunexian is an intravenous Factor XIa inhibitor being studied for acute and critical-care settings, including complex cardiac surgery.